Idarubicin
- Generic Name
- Idarubicin
- Brand Names
- Idamycin
- Drug Type
- Small Molecule
- Chemical Formula
- C26H27NO9
- CAS Number
- 58957-92-9
- Unique Ingredient Identifier
- ZRP63D75JW
- Background
An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
- Indication
For the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.
- Associated Conditions
- Acute Myeloid Leukemia
- Associated Therapies
- -
A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Interventions
- Drug: AzacitidineDrug: DecitabineDrug: CytarabineDrug: DaunorubicinDrug: EtoposideCombination Product: ITMHADrug: IdarubicinDrug: FludarabineDrug: MitoxantroneDrug: SorafenibDrug: Erwinia asparaginaseDrug: G-CSFDrug: DexrazoxaneDrug: Asparaginase Erwinia Chrysanthemi, Recombinant-RywnBiological: Stem Cell Transplant
- First Posted Date
- 2017-05-23
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 206
- Registration Number
- NCT03164057
- Locations
- ๐บ๐ธ
Rady Children's Hospital and Health Center, San Diego, California, United States
๐บ๐ธChildren's Hospital of Central California, Madera, California, United States
๐บ๐ธChildren's Hospital of Orange County, Orange, California, United States
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
- Conditions
- Interventions
- Drug: PrednisoneDrug: VincristineDrug: DaunorubicinDrug: PegaspargaseDrug: ErwinaseยฎDrug: CyclophosphamideDrug: CytarabineDrug: MercaptopurineDrug: DasatinibDrug: MethotrexateDrug: BlinatumomabDrug: DexamethasoneDrug: RuxolitinibDrug: ThioguanineDrug: BortezomibDrug: Asparaginase Erwinia chrysanthemi (recombinant)-rywnDrug: Calaspargase PegolDrug: DoxorubicinDrug: EtoposideDrug: NelarabineDrug: ClofarabineDrug: VorinostatDrug: Idarubicin
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 790
- Registration Number
- NCT03117751
- Locations
- ๐บ๐ธ
Children's Hospital of Michigan, Detroit, Michigan, United States
๐บ๐ธSt. Jude Affiliate Clinic - Novant Health Hemby Children's Hospital, Charlotte, North Carolina, United States
๐ฆ๐บThe Royal Children's Hospital Melbourne, Parkville, Victoria, Australia
Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2019-03-22
- Target Recruit Count
- 60
- Registration Number
- NCT02937662
- Locations
- ๐จ๐ณ
Institute of Hematology & Blood Diseases Hospital, Tianjin, China
Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2016-09-19
- Last Posted Date
- 2018-05-04
- Lead Sponsor
- Massachusetts General Hospital
- Registration Number
- NCT02905994
- Locations
- ๐บ๐ธ
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
๐บ๐ธMassachusetts general Hospital, Boston, Massachusetts, United States
Optimization of Therapy in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment
- Conditions
- Interventions
- Drug: RituximabProcedure: Cranial irradiationDrug: NelarabineDrug: IdarubicinDrug: PEG-AsparaginaseDrug: ImatinibDrug: FludarabineDrug: DexamethasoneDrug: CyclophosphamideDrug: VincristineDrug: MethotrexateProcedure: Stem cell transplantationDrug: MercaptopurineDrug: CytarabineDrug: VP16Drug: VindesineDrug: Daunorubicin (DNR)Drug: AdriamycinDrug: Prednisolone
- First Posted Date
- 2016-08-26
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 1000
- Registration Number
- NCT02881086
- Locations
- ๐ฉ๐ช
University Hospital of Frankfurt (Main), Frankfurt (Main), Germany
Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2016-08-19
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Chimerix
- Target Recruit Count
- 75
- Registration Number
- NCT02873338
- Locations
- ๐บ๐ธ
Franciscan St. Francis Health, Indianapolis, Indiana, United States
๐บ๐ธBaylor Research Institute/Baylor Sammons Cancer Center/Baylor University Medical Center, Dallas, Texas, United States
๐บ๐ธUniversity of Cincinnati, Cincinnati, Ohio, United States
Optimal Treatment Strategy Based on for Pediatric AML
- First Posted Date
- 2016-07-28
- Last Posted Date
- 2016-07-28
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 350
- Registration Number
- NCT02848183
- Locations
- ๐ฐ๐ท
Chonnam National University Hwasun Hospital, Chonnam, Korea, Republic of
๐ฐ๐ทSt. Mary Hospital, Seoul, Korea, Republic of
๐ฐ๐ทSamsung Medical Center, Seoul, Korea, Republic of
A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2016-07-18
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- NewLink Genetics Corporation
- Target Recruit Count
- 54
- Registration Number
- NCT02835729
- Locations
- ๐บ๐ธ
Augusta University, Augusta, Georgia, United States
๐บ๐ธUniversity of Maryland, Baltimore, Maryland, United States
Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2016-07-15
- Last Posted Date
- 2021-08-19
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 7
- Registration Number
- NCT02834390
Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: CytarabineDrug: CyclophosphamideDrug: DasatinibDrug: IdarubicinDrug: IdelalisibDrug: DexamethasoneDevice: In Vitro Kinase Inhibitor AssayDrug: Doxorubicin HydrochlorideDrug: Ponatinib HydrochlorideDrug: Ruxolitinib PhosphateDrug: Sorafenib TosylateDrug: Leucovorin CalciumDrug: Sunitinib MalateDrug: MethotrexateDrug: Methylprednisolone Sodium SuccinateBiological: RituximabDrug: Vincristine Sulfate
- First Posted Date
- 2016-05-20
- Last Posted Date
- 2020-05-26
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 7
- Registration Number
- NCT02779283
- Locations
- ๐บ๐ธ
OHSU Knight Cancer Institute, Portland, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.